POPULARITY
37 episodes with cholangitis
6 episodes with cholangitis
11 episodes with cholangitis
6 episodes with cholangitis
4 episodes with cholangitis
8 episodes with cholangitis
2 episodes with cholangitis
2 episodes with cholangitis
2 episodes with cholangitis
In der Diagnostik und Therapie häufiger cholestatischer Erkrankungen, wie der primär biliären Cholangitis, hat sich die letzten Jahre einiges getan. Und auch bei Seltenheiten gibt es Neues zu berichten. Prof. Markus Lerch spricht in dieser Folge mit Prof. Verena Keitel-Anselmino über die Relevanz von altbekannten und neuen Leberwerten für die systematische Abklärung, über als Hepatitis getarnte Gallenwegserkrankungen und neue therapeutische Möglichkeiten.
In this episode Paul, John and Will have a conversation about Primary Sclerosing Cholangitis (PSC). What does it mean to have this condition that continues to baffle medical science.
Staff at the NIHR Nottingham Clinical Research Facility talk about the UCAB trial. The facility worked with Swedish pharmaceutical Umecrime Cognition to study using a new molecule as a treatment for Primary Biliary Cholangitis (PBC) for patients with severe symptoms of fatigue and cognitive impairment. Quick takeaways - • one of only two UK locations for first stage drug trial • kept to tight, complex timelines • exceeded recruitment targets by building on existing relationships • patients praised care and treatment The NIHR Nottingham Clinical Research Facility (CRF) was one of just two centres worldwide – and the only UK facility – to conduct the first part of a clinical study. We were picked because of our expertise in liver disease. We hosted five patients on a purpose-built inpatient ward within the CRF, to confirm the correct dose of the molecule. During their seven-day stay, our team of research nurses and physicians assessed and cared for the patients around the clock. Nottingham CRF has 18 adult and five paediatric inpatient beds dedicated for research, alongside our dedicated outpatient and specialist clinics. In total, there is over 3,400m² of clinical space at our CRF. The PBC study was a randomised, double-blinded and placebo controlled two-part study to evaluate the pharmacokinetics, safety and tolerability, and preliminary efficacy of two dose levels of the new drug. There's more about it at https://nottinghamcrf.nihr.ac.uk/facilities/case-studies Follow us on Twitter: @NottmBRC Follow us on Instagram: @NottmHealthScience Follow us on Facebook: https://www.facebook.com/ResearchNottingham Watch a video explainer about clinical trials: https://youtu.be/SWS4FCSMWAQ Read more at https://www.nottinghamresearch.org/get-involved and https://www.nuh.nhs.uk/take-part-in-a-trial and https://www.nuh.nhs.uk/researchvolunteers Email us at getinvolved@nuh.nhs.uk
How familiar are you with emerging therapies for primary biliary cholangitis (PBC)? Credit available for this activity expires: 3/28/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000562?ecd=bdc_podcast_libsyn_mscpedu
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.(00:32)Could you please provide a little information about your background? (02:09)Please give a brief overview of the new test panels. (05:35)Which patients should have this testing and when should it be performed? (09:49)What alternative test options are available, and how do those compare to our testing at Mayo Clinic Laboratories? (13:15)How are the results used in patient care?
CME credits: 1.00 Valid until: 31-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/primary-biliary-cholangitis-is-risky-business/16644/ Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00 Valid until: 31-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/primary-biliary-cholangitis-the-phenotype-it-is-a-changin/16641/ Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00 Valid until: 31-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/primary-biliary-cholangitis-vs-primary-sclerosing-cholangitis-do-you-know-the-difference/16642/ Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00 Valid until: 31-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/primary-biliary-cholangitis-a-natural-history-lesson/16643/ Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00 Valid until: 31-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/goals-of-treatment-for-primary-biliary-cholangitis-a-balancing-act/16645/ Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00 Valid until: 31-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/treatment-for-primary-biliary-cholangitis-whos-on-first-whos-on-second/16647/ Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00 Valid until: 31-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-treatment-pipeline-for-primary-biliary-cholangitis-sorting-out-the-ppars/16649/ Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00 Valid until: 31-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-treatment-pipeline-for-primary-biliary-cholangitis-ibat-inhibition-and-beyond/16650/ Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
In this episode, we review the high-yield topic of Secondary Biliary Cholangitis from the Gastrointestinal section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets
A Christmas Day Miracle, by Dean and Talya Rotbart, is adapted from their 2020 biography of Margaret and Riyaz Adat, titled Improbable Lives: A Scot, A Tanzanian, and Their Canadian Love Story. A true-life, inspirational adult yuletide tale, A Christmas Day Miracle offers a universal message — regardless of readers' religious beliefs — about the wonder and power of life's unexpected blessings. Since the book was first published two years ago, it has become a perennial holiday favorite. We hope you enjoy it.
Podcast summary of articles from the October 2023 edition of the Journal of Emergency Medicine from the American Academy of Emergency Medicine. Topics include acute cholangitis, procedural sedation, urine drug screens, burns, and non-convolsive status epilepticus. Guest speaker is Dr. Dustyn Whitesel.
Did you know that 80% of children with biliary atresia who undergo a Kasai procedure will still require liver transplant at some point in their life? Dr. Bade, a pediatric gastroenterologist, joins medical students Tucker Oliver and Sarah Chappell to discuss evaluation and management of infants with biliary atresia. Specifically, they will: Discuss the presentation and diagnosis of biliary atresia Explain pathophysiology behind jaundice Discuss preoperative and postoperative recommendations for the Kasai procedure Review complications and outcomes of the Kasai procedure Share advice for navigating the diagnosis of biliary atresia with families Special thanks to Dr. Rebecca Yang and Dr. Jennifer Tucker for peer reviewing this episode. FREE CME Credit (requires free sign-up): Link Coming Soon! References: 1] P. J. Lupo et al., “Population-based birth defects data in the United States, 2010-2014: A focus on gastrointestinal defects.,” Birth Defects Res, vol. 109, no. 18, pp. 1504–1514, Nov. 2017, doi: 10.1002/bdr2.1145. [2] J. L. Hartley, M. Davenport, and D. A. Kelly, “Biliary atresia,” The Lancet, vol. 374, no. 9702, pp. 1704–1713, Nov. 2009, doi: 10.1016/S0140-6736(09)60946-6. [3] S. S. Sundaram, C. L. Mack, A. G. Feldman, and R. J. Sokol, “Biliary atresia: Indications and timing of liver transplantation and optimization of pretransplant care.,” Liver Transpl, vol. 23, no. 1, pp. 96–109, Jan. 2017, doi: 10.1002/lt.24640. [4] D. Volpert, F. White, M. J. Finegold, J. Molleston, M. DeBaun, and D. H. Perlmutter, “Outcome of Early Hepatic Portoenterostomy for Biliary Atresia,” J Pediatr Gastroenterol Nutr, vol. 32, no. 3, pp. 265–269, Mar. 2001, doi: 10.1097/00005176-200103000-00006. [5] R. Fawaz et al., “Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.,” J Pediatr Gastroenterol Nutr, vol. 64, no. 1, pp. 154–168, Jan. 2017, doi: 10.1097/MPG.0000000000001334. [6] P. H. Y. Chung et al., “Life long follow up and management strategies of patients living with native livers after Kasai portoenterostomy.,” Sci Rep, vol. 11, no. 1, p. 11207, May 2021, doi: 10.1038/s41598-021-90860-w. [7] E. H. Gad, Y. Kamel, T. A.-H. Salem, M. A.-H. Ali, and A. N. Sallam, “Short- and long-term outcomes after Kasai operation for type III biliary atresia: Twenty years of experience in a single tertiary Egyptian center-A retrospective cohort study.,” Ann Med Surg (Lond), vol. 62, pp. 302–314, Feb. 2021, doi: 10.1016/j.amsu.2021.01.052. [8] A. M. Calinescu et al., “Cholangitis Definition and Treatment after Kasai Hepatoportoenterostomy for Biliary Atresia: A Delphi Process and International Expert Panel.,” J Clin Med, vol. 11, no. 3, Jan. 2022, doi: 10.3390/jcm11030494. [9] S. Kiriyama et al., “Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos),” J Hepatobiliary Pancreat Sci, vol. 25, no. 1, pp. 17–30, Jan. 2018, doi: 10.1002/jhbp.512. [10] K. Decharun, C. M. Leys, K. W. West, and S. M. E. Finnell, “Prophylactic Antibiotics for Prevention of Cholangitis in Patients With Biliary Atresia Status Post-Kasai Portoenterostomy,” Clin Pediatr (Phila), vol. 55, no. 1, pp. 66–72, Jan. 2016, doi: 10.1177/0009922815594760. [11] E. Jung, W.-H. Park, and S.-O. Choi, “Late complications and current status of long-term survivals over 10 years after Kasai portoenterostomy.,” J Korean Surg Soc, vol. 81, no. 4, pp. 271–5, Oct. 2011, doi: 10.4174/jkss.2011.81.4.271. [12] S. S. Sundaram et al., “Health related quality of life in patients with biliary atresia surviving with their native liver.,” J Pediatr, vol. 163, no. 4, pp. 1052–7.e2, Oct. 2013, doi: 10.1016/j.jpeds.2013.04.037. [13] B. L. Shneider et al., “Efficacy of fat-soluble vitamin supplementation in infants with biliary atresia.,” Pediatrics, vol. 130, no. 3, pp. e607-14, Sep. 2012, doi: 10.1542/peds.2011-1423. [14] J. P. Molleston and B. L. Shneider, “Preventing variceal bleeding in infants and children: is less more?,” Gastroenterology, vol. 145, no. 4, pp. 719–22, Oct. 2013, doi: 10.1053/j.gastro.2013.08.026. [15] G. Grisotti and R. A. Cowles, “Complications in pediatric hepatobiliary surgery,” Semin Pediatr Surg, vol. 25, no. 6, pp. 388–394, Dec. 2016, doi: 10.1053/j.sempedsurg.2016.10.004. [16] F. R. Sinatra, “Consultation with the Specialist: Liver Transplantation for Biliary Atresia,” Pediatr Rev, vol. 22, no. 5, pp. 166–168, May 2001, doi: 10.1542/pir.22-5-166. [17] I. Sriram and D. Nicklas, “Biliary Atresia,” Pediatr Rev, vol. 43, no. 11, pp. 659–661, Nov. 2022, doi: 10.1542/pir.2021-005287. [18] L. H. Rodijk et al., “Parental wellbeing after diagnosing a child with biliary atresia: A prospective cohort study.,” J Pediatr Surg, vol. 57, no. 4, pp. 649–654, Apr. 2022, doi: 10.1016/j.jpedsurg.2021.05.026. [19] A. Sanchez-Valle, N. Kassira, V. C. Varela, S. C. Radu, C. Paidas, and R. S. Kirby, “Biliary Atresia: Epidemiology, Genetics, Clinical Update, and Public Health Perspective.,” Adv Pediatr, vol. 64, no. 1, pp. 285–305, Aug. 2017, doi: 10.1016/j.yapd.2017.03.012.
Thank you for listening to this episode of "Health and Fitness" from the Nezpod Studios! Enjoy your night or the start of your day, spiced by our top-notch health and fitness/wellness updates coined from the best sources around the globe: made only for your utmost enjoyment and enlightenment… Click on subscribe to get more spicy episodes for free! See you again soon on the next episode of Health and Fitness Updates! Learn more about your ad choices. Visit megaphone.fm/adchoices
Thank you for listening to this episode of "Health and Fitness" from the Nezpod Studios! Enjoy your night or the start of your day, spiced by our top-notch health and fitness/wellness updates coined from the best sources around the globe: made only for your utmost enjoyment and enlightenment… Click on subscribe to get more spicy episodes for free! See you again soon on the next episode of Health and Fitness Updates! Learn more about your ad choices. Visit megaphone.fm/adchoices
Thank you for listening to this episode of "Health and Fitness" from the Nezpod Studios! Enjoy your night or the start of your day, spiced by our top-notch health and fitness/wellness updates coined from the best sources around the globe: made only for your utmost enjoyment and enlightenment… Click on subscribe to get more spicy episodes for free! See you again soon on the next episode of Health and Fitness Updates! Learn more about your ad choices. Visit megaphone.fm/adchoices
Thank you for listening to this episode of "Health and Fitness" from the Nezpod Studios! Enjoy your night or the start of your day, spiced by our top-notch health and fitness/wellness updates coined from the best sources around the globe: made only for your utmost enjoyment and enlightenment… Click on subscribe to get more spicy episodes for free! See you again soon on the next episode of Health and Fitness Updates! Learn more about your ad choices. Visit megaphone.fm/adchoices
Approach to workup of cholangitis, chronic cholecystitis, Gallstone Ileus, Cholangiocarcinoma including Klatskin tumor, Carcinoma of GB and Pancreas At the end some house-cleaning on iatrogenic complications of gallstone disease after ERCP and other procedures are discussed (including bile duct injury and bile leak); For SOD refer to previous episode on cholecystitis management and complications of cholecystectomy.
Questions & cases regarding diagnostic workup and management for PBC, PSC, Alcoholic & Non-Alcoholic Fatty Liver Disease (steatosis, steatohepatitis), and Vascular Hepatopathy
In this episode, we review the high-yield topic of Primary Sclerosing Cholangitis from the Gastrointestinal section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://podcasters.spotify.com/pod/show/medbulletsstep1/message
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Alan Bonder, MD According to this clinician, the most important thing for primary biliary cholangitis (PBC) patients is the diagnosis, and anyone with abnormal liver tests should be sent an antimitochondrial antibody (AMA). Dive into this interview with host Dr. Peter Buch and Dr. Alan Bonder, Assistant Professor of Medicine and the Medical Director of Liver Transplantation at Beth Israel Medical Center in Boston.
This episode covers primary sclerosing cholangitis.Written notes can be found at https://zerotofinals.com/medicine/gastroenterology/primarysclerosingcholangitis/ or in the gastroenterology section of the 2nd edition of the Zero to Finals medicine book.The audio in the episode was expertly edited by Harry Watchman.
This episode covers primary biliary cholangitis.Written notes can be found at https://zerotofinals.com/medicine/gastroenterology/primarybiliarycholangitis/ or in the gastroenterology section of the 2nd edition of the Zero to Finals medicine book.The audio in the episode was expertly edited by Harry Watchman.
In this episode, we discuss the clinical presentation, severity grading, investigations and management for patients presenting with cholecystitis or cholangitis. Our medicine minute discusses a promising new technique for patients with non-operative cholecystitis. Podcast written by: Drs. Amine Zoughlami and Ikram Abow-Mohamed (Internal Medicine residents)Reviewed by: Dr. Constantine Soulellis (Gastroenterology) and Dr. Sanabelle Zaabat (Internal Medicine)Sound editing by: Alison laiSupport the show
PSC Partners Seeking a Cure is pleased to present Living With PSC, a podcast moderated by Niall McKay. Each month, this podcast explores the latest research and knowledge about primary sclerosing cholangitis (PSC), a rare liver disease. From patient stories, to the latest research updates from PSC experts, to collaborations that are necessary to find better treatments and a cure, this podcast has it all! In epidode 37 of the Living with PSC Podcast, Host Niall McKay talks with Dr. Laura Cristoferi, hepatologist, clinical research fellow, and PhD candidate, at Milano Bicocca University in Italy. They discuss PSC diagnosis and disease progression, the importance of PSC registries to share knowledge and improve research, various PSC therapies, and more. "We are building a national PSC registry in Italy," says Dr. Cristoferi. "We are trying to build a network in order to improve knowledge for diagnosis and management of this disease...and in order to have a rapid connection in case of clinical trials. Using this registry, we will have precise epidemiological data." Dr. Cristoferi highlights various research endeavors including her project aimed at discovering biomarkers to enable a more precise determination of PSC disease progression over time.
In this episode, we review the high-yield topic of Primary Sclerosing Cholangitis from the Gastrointestinal section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets
Ascending Cholangitis with Drs. Jamil & Qumseya
At least 5 agents that target the peroxisome proliferator-activated receptor (PPAR) are in clinical studies in primary biliary cholangitis (PBC). Are you aware of the latest data? Credit available for this activity expires: 2/21/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/[articleID]?ecd=bdc_podcast_libsyn_mscpedu
PSC Partners Seeking a Cure is pleased to present Living With PSC, a podcast moderated by Niall McKay. Each month, this podcast explores the latest research and knowledge about primary sclerosing cholangitis (PSC), a rare liver disease. From patient stories, to the latest research updates from PSC experts, to collaborations that are necessary to find better treatments and a cure, this podcast has it all! In episode 36 of the Living with PSC Podcast, Host Niall McKay talks about drug repurposing with Ania Korsunska, MA, Biomedical Leadership Fellow and ROADMAP Project Lead, Castleman Disease Collaborative Network (CDCN). "(Drug repurposing) is an opportunity to utilize existing drugs that are in development or already approved and redirect for the rare disease space," says Korsunska. "It's potentially cheaper than novel drug development, potentially faster. It's potentially easier to get these drugs into a position that a doctor can actually prescribe them."
PSC Partners Seeking a Cure is pleased to present Living With PSC, a podcast moderated by Niall McKay. Each month, this podcast explores the latest research and knowledge about primary sclerosing cholangitis (PSC), a rare liver disease. From patient stories, to the latest research updates from PSC experts, to collaborations that are necessary to find better treatments and a cure, this podcast has it all! In episode 35 of the Living with PSC Podcast, Host Niall McKay talks with Dr. Kidist Yimam, Medical Director of the Autoimmune Liver Disease Program at California Pacific Medical Center. She is also a member of the PSC Partners Diversity, Equity, and Inclusion Working Group. In this podcast, they discuss health inequalities in PSC, including provider bias, lack of access to care, delay in diagnosis, importance of diversity in clinical trials, and more. "It is not unusual to hear from some of our minority patients that they've been told by other providers that PSC affects people who are Caucasian, and they shouldn't be affected by the disease, leading to a delay in diagnosis of PSC, and even putting them at risk of poorer outcomes," says Dr. Yimam. McKay and Yimam also discuss how including a diverse group of people in PSC natural history studies will allow researchers to better understand how genetics, socio-economic factors, cultural biases, and more affect the search for treatments and a cure for PSC. To make that happen, diversity is needed within the PSC Partners Patient Registry.
References Dr Guerra's immunology lecture notes J Vis Exp. 2013; (81): 50966 Front Immunol. 2019; 10: 1309. Infect Immun. 2013 Dec; 81(12): 4478–4489. Immunity 2022. Volume 55 Issue 8 Pages 1370-1385.e8 --- Send in a voice message: https://anchor.fm/dr-daniel-j-guerra/message
PSC Partners Seeking a Cure is pleased to present Living With PSC, a podcast moderated by Niall McKay. Each month, this podcast explores the latest research and knowledge about primary sclerosing cholangitis (PSC), a rare liver disease. From patient stories, to the latest research updates from PSC experts, to collaborations that are necessary to find better treatments and a cure, this podcast has it all! In episode 34 of the Living with PSC Podcast, Host Niall McKay talks with Nicola Tessier, a post-transplant PSC patient, about her PSC diagnosis, dealing with symptoms, MELD score issues for PSC patients, receiving a living donor liver transplant from her brother, having children post-transplant, and much more. "The need for a liver transplant was heavily driven by my (increased) risk for cholangiocarcinoma," says Tessier. "On paper, I looked less sick than I really was. So, the option of a living donor was a better fit for me." She received 56% of her younger brother's liver. "It was a very special day," she says.
Although the etiology of primary sclerosing cholangitis (PSC) is poorly understood it is a progressive disease characterized by inflammation of the bile ducts. This week I interview RD Brittany Roman-Green and we discuss primary sclerosing cholangitis, its relationship to ulcerative colitis and what the current research says about it. Brittany Roman-Green is the founder of Romanwell and is an IBD focused registered dietitian nutritionist, certified personal trainer, and behavior change specialist. Brittany's the national coleader of the diet and nutrition national scientific advisory committee for the Crohn's and Colitis Foundation and the national leader of the registered dietitians in IBD practice group for the Academy of Nutrition and Dietetics. Brittany has lived with ulcerative colitis for over 20 years and also has IBS and PSC. We talk about: What is primary sclerosing cholangitis (PSC) What are the symptoms of PSC? Why do people with IBD develop PSC? Does nutrition influence PSC management? Nutrition management of IBD, including a discussion about inflammatory foods The use of restrictive diets and their potential side effects The 2020 International Organization for the study of IBD guidelines Connect with Roman-Green on her website at romanwell.com on Instagram @weareromanwell or on her Facebook here as well! You can also checkout their IBD starter kit that's full of tips for advocating for oneself when you have IBD.
In this episode, we review the high-yield topic of Primary Biliary Cholangitis from the Gastrointestinal section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets
PSC Partners Seeking a Cure is pleased to present Living With PSC, a podcast moderated by Niall McKay. Each month, this podcast explores the latest research and knowledge about primary sclerosing cholangitis (PSC), a rare liver disease. From patient stories, to the latest research updates from PSC experts, to collaborations that are necessary to find better treatments and a cure, this podcast has it all! In episode 33 of the Living with PSC Podcast, Host Niall McKay talks with Hepatologist and Senior Research Clinician Theo Heller, MD, and Hepatology Fellow Gracia Viana, MD, National Institute for Health (NIH) Clinical Center, about their primary sclerosing cholangitis (PSC) study. "We want to study the evolution of PSC," says Dr. Heller. "We're proposing a study that has the potential of unraveling some of the most fundamental aspects of the disease." Information about this study will be sent to PSC Partners Registry participants. If you are a PSC patient but have not yet joined the Patient Registry, now would be a good time. www.pscpartnersregistry.org Questions about the Registry? Email: registrycoordinator@pscpartners.org
PSC Partners Seeking a Cure is pleased to present Living With PSC, a podcast moderated by Niall McKay. Each month, this podcast explores the latest research and knowledge about primary sclerosing cholangitis (PSC), a rare liver disease. From patient stories, to the latest research updates from PSC experts, to collaborations that are necessary to find better treatments and a cure, this podcast has it all! In episode 32, Host Niall McKay talks with Dr. Espen Melum, MD, PhD, Norwegian PSC Research Center, about a new discovery in PSC research. Dr. Melum and his colleagues have discovered antigens that activate T cells, or MAIT cells, that are present in a number of PSC patients participating in the study. These findings point to the role of contaminated bile in the onset of PSC.
Welcome to the 11th episode of 5 Minute Medicine! In this episode, we will be covering the complex pathology of Acute (Ascending) Cholangitis. We will discuss the pathophysiology, risk factors, symptoms, clinical features, diagnosis and treatment! All of the highest yield information is covered, with many easy ways to remember the important features of this pathology, including the 6Fs of cholelithiasis (gallstone formation) and Reynold's pentad! We hope you are enjoying the content so far! Follow us on Spotify to be notified of our releases. We would really appreciate if you rate us 5 stars and give us a review on Apple Podcasts if you have the time too, as this really helps our discoverability ❤️ follow our Ig @5.min.medicine for quizzes and notes on the topics!
Welcome to the emDOCs.net podcast! Join us as we review our high-yield posts from our website emDOCs.net. Today on the emDOCs cast with Brit Long, MD (@long_brit), we cover a significant biliary pathology: cholangitis. To continue to make this a worthwhile podcast for you to listen to, we appreciate any feedback and comments you may have for us. Please let us know!Subscribe to the podcast on one of the many platforms below:Apple iTunesSpotifyGoogle Play
PSC Partners Seeking a Cure is pleased to present Living With PSC, a podcast moderated by Niall McKay. Each month, this podcast explores the latest research and knowledge about primary sclerosing cholangitis (PSC), a rare liver disease. From patient stories, to the latest research updates from PSC experts, to collaborations that are necessary to find better treatments and a cure, this podcast has it all! In episode 30, Host Niall McKay talks with Joanne Hatchett, Medical Science Liaison for PSC Partners, about the upcoming 2022 Annual PSC Partners Conference, June 2-5, now in a virtual format. This is the first of two conversations about this topic. "Dr. Josh Korzenik of Brigham and Women's and Dr. Dan Pratt of Mass General Hospital have been working with our PSC team to plan an amazing conference this year," says Hatchett. "Sessions will focus on featuring the patient's voice, because that's at the heart of the conference, (and we're also planning) many ways to meet, (learn), and socialize before during and after the (virtual event).
PSC Partners Seeking a Cure is pleased to present Living With PSC, a podcast moderated by Niall McKay. Each month, this podcast explores the latest research and knowledge about primary sclerosing cholangitis (PSC), a rare liver disease. From patient stories, to the latest research updates from PSC experts, to collaborations that are necessary to find better treatments and a cure, this podcast has it all! In episode 31, Host Niall McKay talks with Josh Korzenik, MD, Brigham and Women's Hospital, and Dan Pratt, MD, Massachusetts General Hospital, about the upcoming 2022 Annual PSC Partners Conference, June 2-5, now in a virtual format. This is the second of two conversations about this Conference. "It's going to be a slightly different and very exciting conference," says Dr. Korzenik. "It's envisioning a very different kind of future for PSC where there's a broader engagement of everybody, and it's really becoming much more of an international community, which is very exciting." Dr. Pratt agrees, adding, "An exciting research initiative that will be rolled out at the conference is the WIND Initiative (Worldwide Integration of Natural History Databases), which will, hopefully, accelerate our identification of new therapies for PSC."
In this episode, we review the high-yield topic of Ascending Cholangitis from the Gastrointestinal section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets
In this episode, we review the high-yield topic of Primary Biliary Cholangitis from the Gastrointestinal section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbulletsIn this episode --- Send in a voice message: https://anchor.fm/medbulletsstep1/message
This episode covers acute cholangitis.Written notes can be found at https://zerotofinals.com/surgery/general/acutecholangitis/ or in the general surgery section of the Zero to Finals surgery book.The audio in the episode was expertly edited by Harry Watchman.
This episode covers acute cholecystitis.Written notes can be found at https://zerotofinals.com/surgery/general/acutecholecystitis/ or in the general surgery section of the Zero to Finals surgery book.The audio in the episode was expertly edited by Harry Watchman.
© 2020-2025 Ivy Podcast Discovery LLC
